SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
Story summaryINCHEON, South Korea, March 18, 2026 /PRNewswire/ -- SK bioscience announced on 18 that it has entered into a funding agreement with the Research Investment for Global Health Technology Foundation (RIGHT Foundation) to receive financial support for early clinical development of its RSV (respiratory syncytial virus) …
Read at The Korea HeraldOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.